Drug Profile
Interferon alpha hybrid - Alfacyte
Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator University of Strathclyde
- Developer Alfacyte; University of Edinburgh
- Class Antiallergics; Antineoplastics; Interferons; Skin disorder therapies
- Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors; Interleukin-22 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Autoimmune disorders; Food hypersensitivity
Highest Development Phases
- No development reported Cancer; Food hypersensitivity; Psoriasis
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for research development in Cancer in United Kingdom (PO)
- 28 Sep 2020 No recent reports of development identified for research development in Psoriasis in United Kingdom (Topical)
- 28 Aug 2019 No recent reports of development identified for research development in Food-hypersensitivity in United Kingdom (PO)